Metaxalone

Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia[1][2].

Product Specifications

CAS Number

[1665-48-1]

Product Name Alternative

AHR438; NSC170959

UNSPSC

12352005

Hazard Statement

H302

Target

NF-κB; PGC-1α

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Metaxalone.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1OC(COC2=CC(C)=CC(C)=C2)CN1

Molecular Formula

C12H15NO3

Molecular Weight

221.26

Precautions

H302

References & Citations

[1]Pallio G, D'Ascola A, Cardia L, et al. MAO-A Inhibition by Metaxalone Reverts IL-1β-Induced Inflammatory Phenotype in Microglial Cells. Int J Mol Sci. 2021;22 (16) :8425. |[2]Stanko JR. Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner. Cranio. 1990 Jul;8 (3) :234-43.